Cargando…
Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease
Currently approved therapies for age-related macular degeneration (AMD) are inhibitors against vascular endothelial growth factor (VEGF), which is a major contributor to the pathogenesis of neovascular AMD (nAMD). Intravitreal injections of anti-VEGF drugs have shown dramatic visual benefits for AMD...
Autores principales: | Matsuda, Yusaku, Nonaka, Yosuke, Futakawa, Satoshi, Imai, Hirotaka, Akita, Kazumasa, Nishihata, Toshiaki, Fujiwara, Masatoshi, Ali, Yusuf, Bhisitkul, Robert B., Nakamura, Yoshikazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716068/ https://www.ncbi.nlm.nih.gov/pubmed/31454678 http://dx.doi.org/10.1016/j.omtn.2019.07.018 |
Ejemplares similares
-
Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain
por: Jin, Ling, et al.
Publicado: (2016) -
Screening and Improvement of an Anti-VEGF DNA Aptamer
por: Nonaka, Yoshihiko, et al.
Publicado: (2010) -
A Chymase Inhibitory RNA Aptamer Improves Cardiac Function and Survival after Myocardial Infarction
por: Jin, Denan, et al.
Publicado: (2018) -
The Effect of Anti-Autotaxin Aptamers on the Development of Proliferative Vitreoretinopathy
por: Hanazaki, Hirotsugu, et al.
Publicado: (2023) -
Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
por: Nakamura, Yoshikazu
Publicado: (2021)